Objective The 2016 Chinese guidelines for the management of dyslipidemia recommended mixed rules that centered around a 10% 10-year risk threshold to initiate statins for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). The present study aimed to evaluate the cost-effectiveness of the guideline statin-initiation strategy and alternative strategies. Methods A decision analytic model using discrete event simulation with event probabilities based on a validated ASCVD risk prediction tool for Chinese was constructed. Risk factor inputs were from the dataset of a nationally representative survey of middle-aged and elderly Chinese. Data of statin treatment effectiveness were from a published meta-analysis. Other key input data were identified from the literature or relevant databases. The strategies we evaluated were the guideline strategy, a 15% 10-year risk threshold strategy and a 20% 10-year risk threshold strategy. After excluding any extended dominance strategies, the incremental costs per quality-adjusted life year (QALY) gained of each strategy was calculated. Results The 20% 10-year risk threshold strategy was an extended dominance option. The incremental costs per QALY gained from the 15% 10-year risk threshold strategy compared with no treatment and the guideline strategy compared with the 15% 10-year risk threshold strategy were CN¥69,309 and CN¥154,944, respectively. The results were robust in most sensitivity analyses. Conclusions The guideline strategy and the 15% 10-year risk threshold strategy are optimal when using the three times and the two times the gross domestic product per capita willingness-to-pay standards, respectively.
Introduction
Dyslipidemia, mainly characterized by an elevated level of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), or TC to high-density lipoprotein cholesterol (HDL-C) ratio, is an important risk factor of atherosclerotic cardiovascular disease (ASCVD) [1, 2] . Statin therapy is an effective way to treat dyslipidemia [3] and is recommended by clinical guidelines in various regions to reduce the risk of major adverse cardiovascular events. However, the recommended criteria to trigger statin intervention varied immensely across guidelines [1, [4] [5] [6] [7] . Whereas most guidelines adopted a mix of risk factor rules and absolute risk rules, some leaned heavily or even exclusively on risk factors. In the guidelines that included absolute risk rules, the 10-year risk threshold to initiate treatment varied substantially [1, [4] [5] [6] 8] . For example, the 2013 American College of Cardiology/American Heart Association (ACC/ AHA) guidelines recommend a 7.5% 10-year ASCVD risk threshold for primary prevention, whereas the Scottish Intercollegiate Guidelines Network recommends a 20% 10-year risk threshold [9] . Although not all guidelines provided the rationale of determining the thresholds [8] , some were supported by cost-effectiveness analyses [6, 10] . For example, a cost-effectiveness analysis that evaluated the 7.5% 10-year ASCVD risk threshold for initiating statin therapy in the 2013 ACC/AHA guidelines showed that the strategy was cost-effective compared with a 10% risk threshold strategy [10] . Another study suggested that the threshold of 15% 10-year risk of coronary heart disease (CHD) and stroke was more cost-effective than the threshold of 5% or 10% risk in the Australian setting [7] . Indeed, it is important to take into consideration the economic consequences when setting the threshold. When the threshold is too low, the incremental health benefit does not offset the additional treatment costs among the less vulnerable subpopulation. On the other hand, an inappropriately high threshold may result in the under-treatment of patients who could potentially benefit from statins. The appropriate risk threshold should be the equilibrium that balances marginal benefit and costs at the population level. More, such risk thresholds cannot be simply adapted from cost-effectiveness analyses in other countries, because of structural differences in health systems and costing. Therefore, it is important to conduct such an analysis for each country individually.
Claiming over 4 million deaths every year, cardiovascular disease (CVD) is the leading cause of mortality in China [11] . In 2016, the China National Center for Cardiovascular Diseases and four specialty committees within the China Medical Association updated the guidelines for the management of dyslipidemia (hereinafter referred to as the guidelines) [1] . While adopting a multi-criteria strategy (see electronic supplementary material Fig. S1 ) among people without any previous cardiovascular events, the guidelines mainly considered a 10% 10-year risk the treatment-initiation threshold [1] . However, the guidelines did not provide the rationales. Another group of researchers and clinicians in China recommended against uncritical initiation of statin therapy for all individuals with risk over the 10% threshold [12] . To date, a formal justification of the guideline treatment-initiation strategy is still lacking. Although the guidelines themselves highlighted the importance of health economic evaluations of treatment [1] , the cost-effectiveness of initiating statin therapy based on the guidelines or alternative risk thresholds has not been documented in China so far. A health economic evaluation of the guideline strategy and alternative thresholds can provide insights on the choice of a threshold that balances resource use and clinical benefit. As such, the objective of the current study was to evaluate and compare the cost-effectiveness of the guideline treatment-initiation criteria and alternative risk thresholds among middle-aged and elderly Chinese for the primary prevention of ASCVD events from the societal perspective.
Methods

Model Structure
A time-driven discrete event simulation (DES) model [13, 14] was constructed to project the lifetime ASCVDrelated outcomes and costs of a cohort of individuals aged 45-89 years. The life expectancy in China is between 76 and 77 years [15] , and the proportion of the 90 years and older population is 0.1% [16] . As such, we stopped simulating the life course at the age of 89 years. Numerically, stopping following individuals at the age of 89 years would generate the same results as if all individuals died after the age of 89 years. The model allowed age-varying ASCVD probabilities, tracking of events and treatment history, and occurrence of more than one event (but different types) per cycle. The model advanced at the yearly cycle to accommodate time-varying probabilities due to change in the values of risk factors [17] . In each cycle of the lifetime course of every individual, fatal and non-fatal CHD and stroke events were simulated based on the annual risk. Individuals were also subject to background death in the model. The structure of the model is illustrated in Fig. 1 . The model was implemented with Excel 2016 VBA code (Microsoft Corporation, Redmond, WA, USA).
Risk of Events
The model used 10-year ASCVD risk equations for men and women estimated by Yang et al. using data from a prospective study on 21,320 Chinese in 2016 [18] . This tool was chosen because it is the most recent CVD risk prediction tool and the only ASCVD-specific risk prediction tool in China to our knowledge. The input risk factors for calculation were age, systolic blood pressure (SBP), TC, HDL-C, waist circumference (WC), smoking, diabetes, geographic region (northern vs. southern China), urban residence, and family history of ASCVD. More details of the equations can be found elsewhere [18] . The equations predicted the 10-year composite probability of a fatal CHD event [all fatal events resulting from acute myocardial infarction (AMI) or other coronary deaths], non-fatal AMI, and both fatal and non-fatal stroke. To utilize the risk prediction in yearly cycles, the 10-year probability was transferred into 1-year probability using the DEALE method [19] . However, the composite probability cannot be directly used to model each of the events since the risk prediction algorithm does not provide event-specific calculation. Therefore, the 1-year composite probability was first divided into 1-year probabilities of CHD (29.46%) and stroke (70.54%) using their respective proportions out of total CHD and stroke events [20] . The CHD events did not include non-fatal non-AMI events. Then, individuals who sustained a CHD event or a stroke in a certain cycle were first determined to be deceased or not within 28 days after the event (Table 1 ) [21] . Hence, any fatal CHD events would be captured by this step. Fatal and non-fatal stroke events followed the same pattern. An individual who survived a CHD event or stroke after 28 days was considered a post-AMI or post-stroke patient and experienced excess mortality which was two times that of background mortality [22] in the cycle of event occurrence as well as all subsequent cycles if no recurrent CHD or stroke events happened. Event probabilities were re-calculated at the beginning of each cycle. Individuals who never had any ASCVD events could die of background mortality in the model (Table 2 ).
Simulation Cohort and Risk Factor Values
At the beginning of the simulation, the model was populated with a cohort of 200,000 individuals without previous ASCVD events whose distributions (see electronic supplementary material Tables S1, S2, and S3) of age, sex, and ASCVD risk factors (other than family history of ASCVD and diabetes) matched the corresponding distributions in the China Health and Retirement Longitudinal Study (CHARLS). CHARLS is a longitudinal aging survey of 45 years and older Chinese and their spouses in China that was devised to be nationally representative [23] . Currently, the data of the 2011, 2013, and 2015 waves of the survey are available. The 2011 wave contained measures of LDL-C, HDL-C, and triglyceride (TG), but not SBP and WC. The 2013 and 2015 waves contained measures of SBP and WC, but not cholesterols. Therefore, we used the 2011 CHARLS data for the distributions of LDL-C, HDL-C and TG, a linear combination of which was used to calculate TC [24] . In addition, SBP, WC, smoking, geographic region, and urban residence distributions were taken from the 2015 CHARLS data. We refer to this cohort as the synthetic CHARLS cohort (see electronic supplementary material Fig. S2 ). Data on family history of ASCVD were rarely reported in CVD risk factor studies in China. Hence, such data were directly taken from the study that developed the risk prediction algorithm [18] . Furthermore, data on diabetes prevalence by age were extracted from a prospective cohort study in the literature [25] . To model the change of time-varying risk factors, the relationships between the corresponding risk factors (HDL-C, TC, SBP, and WC) and age were obtained by conducting cross-sectional linear regressions using CHARLS data (see electronic supplementary material Tables S4 and S5 ). Age-specific diabetes incidence data were obtained from a study in the literature [26] . There is an absence of theories to guide the choice of the cohort size for individual-level AMI acute myocardial infarction, CHD coronary heart disease, CN¥ Chinese Yuan, OR odds ratio a During the immediate stage after an event when the patient could potentially experience acute mortality, the patient also experienced worse quality of life than in the long-term stage. The acute disutility was assumed to last for a month, which was a similar duration to that of the acute mortality stage b The magnitude of the standard error of stroke-related acute disutility as the percentage of the mean was assumed to be the same as that of CHD c These standard errors were for the log of ORs simulations such as DES and microsimulations. Therefore, we experimented with gradually increasing the cohort size and found that the relative difference between results was below 0.5% if the cohort was re-sampled at the size of 200,000 individuals.
Intervention and Treatment Strategies
The guideline treatment-initiation strategy is illustrated in electronic supplementary material Fig. S1 . However, a few items of the criteria in the guidelines allowed either the LDL-C threshold (e.g., 190 mg/dL without diabetes = high risk) or TC threshold (e.g., 278 mg/dL without diabetes = high risk) to accommodate heterogeneous laboratory practices. The practice heterogeneity was not an issue for a simulation study. Hence, we only used LDL-C criteria in the model for the guideline criteria that contained both LDL-C and TC values. Also, the risk used to determine initiation of statin therapy was 10-year risk as opposed to the converted 1-year risk for the simulation of events. Individuals who met the treatment-initiation criteria in a certain cycle started one of the medium-intensity statins (daily doses: atorvastatin 10 mg, lovastatin 20-40 mg, pravastatin 40 mg, rosuvastatin 10 mg, simvastatin 40 mg), the list of which was a reconciliation of the guidelines and a meta-analysis of statins in the literature [1, 3] . High-intensity statin treatment was not analyzed because the guidelines explicitly noted that studies of high-intensity statins among the Chinese population are limited and should only be used with caution [1] . In addition, individuals who experienced an ASCVD event during the simulation were put on treatment regardless of risk and risk factors if not previously treated. The treatment effects of medium-intensity statins on CHD and stroke were based on the meta-analysis (Table 1) . Patients were on treatment for 5 years in the base case. This is the relatively common assumption in the literature of economic analysis of statins [27] [28] [29] , although some studies assumed different treatment durations. Alternative durations (1-year, 3-year, 7-year, and lifetime) were conducted in exploratory analysis. We also carried out analyses of initiating treatment at 15% and 20% 10-year risk. These simulation courses resembled that of the guideline strategy except treatment initiation was only based on the absolute risk and simulated ASCVD event history. The purpose of this was not to deprioritize using cholesterol levels as criteria. Rather, it was to allow the analysis to focus on estimating a clear overall risk threshold. In addition to the treatment strategies, a simulation course of no treatment was run.
Outcome Measures and Inputs
The outcomes of interest in the current study were total ASCVD-related medical costs and quality-adjusted life years (QALYs) of the simulated cohort. Total ASCVDrelated medical costs included statin acquisition costs, hospitalization costs, first-year non-acute medical costs, and subsequent year outpatient visit costs. The input data were from drug winning bid price databases and the literature of medical costs in China (Table 1) . Following the approach in a similar study [7] , we calculated the annual medication acquisition costs by averaging the lowest winning bid prices of the aforementioned statins in local government procurement catalogues across various regions in China in the first quarter of 2018 [30] . Post-AMI and post-stroke individuals were assumed to require one office visit each year in their residual lifetime. Costs were inflated to March 2018 Chinese currency (CN¥) using the China Healthcare Component Consumer Price Indices [31] . The calculation of QALYs used both age-specific utility weights (Table 2) and event-related disutility weights that can be further classified into acute disutility and long-term disutility (only experienced by those who survived the acute stage) ( Table 1 ). The age-specific utility weights were from an EQ-5D survey among the Chinese general population [32] . The acute and long-term disutility weights were extracted from the Global Burden of Disease project and an EQ-5D survey in China among people with chronic conditions [33, 34] . An annual discount rate of 3% was used at the base case.
Intervention Strategy Comparisons
For comparison, the strategies were ordered by discounted per capita costs first. Then, any dominance or extended dominance strategies were removed from the comparison [35, 36] . Next, the incremental cost-effectiveness ratio (ICER), defined as incremental costs per QALY gained, of each strategy that remained in the cascade of comparison was evaluated. Following that, we first examined up to which strategy the ICER was under the cost-effective standard (CN¥178,980) of three times the Chinese gross domestic product (GDP) per capita (3-GDP) in 2017 [37, 38] . The corresponding strategy was then considered the optimal strategy. However, the choice of the cost-effective standard has been a disputable issue in the literature recently [39, 40] . Therefore, we also examined the results against the alternative standards of one times the GDP per capita (1-GDP; CN¥59,660) that is considered highly costeffective [37] and two times the GDP per capita (2-GDP, CN¥119,320), which has also been used in some countries [41, 42] , respectively.
Alternative Scenarios and Sensitivity Analysis
One-way sensitivity analyses were conducted by changing the values of several important input variables, including effects of statins on CHD and stroke, ASCVD risk, statins acquisition costs, annual discount rate, and CHD and stroke 28-day mortality. All variables were increased or decreased by 20% of the base-case value except discount rate, which was changed to 1% and 5%. Also, treatment duration was varied in a set of exploratory analyses. Furthermore, a probabilistic sensitivity analysis (PSA) was conducted by repeating the simulation 350 times with the values of treatment effects, CHD and stroke acute disutility weights, CHD and stroke long-term disutility weights, hospitalization costs of CHD and stroke, and 28-day mortality re-sampled from their respective distributions (Table 1) for each run. The number of repetitions was chosen for feasibility reasons. Specifically, each run of the simulation courses of all four strategies took about 20 min, and 350 repetitions took about 5 days.
Model Validation
The validity of the model was examined from several aspects [43, 44] . The model structure was adapted from statin economic evaluation studies and a DES health economic model in the literature [10, 17, 45] , and was reviewed by a clinical cardiologist in China and two independent health economists in academia. The input data were reviewed by the same panel of experts. We also investigated the face validity, internal validity, and external validity based on model outputs [43] . Face validity was examined by checking whether the incremental QALYs were in comparable orders of magnitude to a similar study in the literature [10] and whether there was monotonic QALY gain as the strategies became less restrictive. To examine internal validity, the expected 1-year probabilities of CHD and stroke events without treatment among select age-sex cohorts (age at multiples of ten, total of 16 data points) were calculated and regressed on the means of the corresponding simulated values (r 2 = 0.9737, see electronic supplementary material Fig. S3 ). External validity was investigated by comparing the simulated stroke incidence of age-sex groups (10-year interval) with that from a prospective study in China [46] (see electronic supplementary material Table S6 ).
Results
The base-case results are presented in Table 3 . The 20% risk threshold strategy was an extended dominance strategy and was removed from the comparison. The ICERs of the 15% risk threshold strategy compared with no treatment and the guideline strategy compared with the 15% risk threshold strategy were CN¥69,309/QALY and CN¥154,944/QALY, respectively. Hence, the guideline strategy was optimal among the three strategies when using the 3-GDP standard. However, no treatment strategy was acceptable when using the 1-GDP standard. More, the 15% risk threshold strategy was optimal when using the 2-GDP standard.
In the one-way sensitivity analyses, results (see electronic supplementary material Table S7 ) were sensitive to changes in the effect of statins on stroke, the price of statin, and the effect of statins on CHD, but remained robust to changes in other parameters. Specifically, the 15% risk threshold strategy became optimal using the 3-GDP standard, whereas none of the treatment strategies were acceptable using the 2-GDP standard if the effect of statins on stroke decreased by 20%. By contrast, increasing the effect of statins on stroke by 20% made the guideline strategy the optimal choice using the 2-GDP standard and the 15% risk threshold strategy the optimal choice using the 1-GDP standard. In addition, decreasing the statin price by 20% resulted in the same changes in the strategy choices from the base case, as did increasing the effect of statins on stroke by 20%. However, the 15% risk threshold strategy became optimal under the 3-GDP constraint when the statin price increased by 20%. Even more, increasing the effect of statins on CHD changed the optimal strategy under the 2-GDP constraint to guideline strategy. The results were robust to alternative treatment duration overall except that the guideline strategy became optimal using the 2-GDP standard with lifetime treatment (see electronic supplementary material Fig. S4 ).
The acceptability curves from the PSA results are displayed in Fig. 2 . Using the 3-GDP cost-effective standard, the guideline strategy had an 87% chance of being the optimal strategy and the 15% risk threshold strategy had a 13% chance. Using the 1-GDP standard, the 15% risk threshold strategy had a 20% chance of being optimal. By contrast, the other strategies had a 0% chance. If the 2-GDP cutoff was to be used, then the 15% risk threshold strategy and the guideline strategy had a 62% chance and a 36% chance of being optimal, respectively. These probabilities did not add up to 100% under the 1-GDP and 2-GDP constraints because none of the treatment strategies were acceptable in some simulations.
Discussion
In healthcare systems that aim to maximize health gains with constrained budgets, the choice of disease prevention and treatment strategies can be informed by understanding cost-effectiveness profiles [47, 48] . This could be particularly important in developing countries where resources are relatively limited. In the present study, we conducted a costeffectiveness analysis of the Chinese guideline strategy and alternative strategies among the middle-aged and elderly population because such evidence is currently absent in the literature. The results of our economic modeling suggest that the statin-initiation strategy to prevent ASCVD events according to the 2016 Chinese guidelines is optimal if the 3-GDP standard is used. However, using a 15% 10-year risk threshold to trigger statin treatment is optimal if the 2-GDP standard is used. When strategies are required to be highly cost-effective, none of the investigated treatment strategies would qualify. The results were robust in most alternative scenarios. Based on our findings, the selection of the costeffectiveness standard affects the choice of the statin initiation strategy. In fact, the cost-effectiveness standard is arguably the most important factor of the decision of optimal Probability of being the optimal strategy
Incremental cost-effectiveness threshold (in thousand CN ) 20% risk threshold 15% risk threshold guideline strategy. From a forward-looking perspective, price is also an important factor. Price is changing over time in the real world, and our sensitivity analyses indicate that the 15% risk threshold would become the optimal strategy if the average price of statins were to decrease by 20% even using the 1-GDP per capita cost-effective standard. This is important because none of the treatment strategies were acceptable under this willingness-to-pay constraint in the base case. The results of analyses using alternative treatment duration indicate that the cost-effectiveness of statin treatment strategies is relatively independent of treatment duration. These results have important implications. Whichever set of criteria for initiation is chosen, patients who meet the criteria can benefit from the treatment at acceptable costs even if they are not able to persist with the treatment for a lifetime.
To our knowledge, three simulation studies in the literature evaluated the clinical guidelines for statin initiation in other countries. Pandya et al. evaluated the cost-effectiveness of the 2013 ACC/AHA guidelines and alternative risk thresholds for the prevention of ASCVD events [10] . Both the Pandya et al. study and the present study created individual patient profiles based on nationally representative surveys, used risk prediction tools to calculate the absolute risk, allowed the risk factor values of everyone to change by age using a regression-based approach to determine the relationship between age and risk factors, incorporated re-evaluation of risk and initiation of treatment in subsequent years after entering the simulation, and used similar estimates of the effect size of statin therapy. However, a difference between the Pandya et al. and the current study was that the former used only one data source for individual characteristics, whereas the latter used several sources to impute risk factors. An innate assumption of our approach was that the different sources could be merged. Another study of US guidelines by Heller et al. [49] modeled the effect of statin therapy on the LDL-C level and associated the LDL-C level with reduction in event risk, whereas the present study modeled the effect using relative risk reduction. A study in the Australian setting by Cobiac et al. [7] modeled event outcomes by first determining 28-day survivors after an event, which is the same as our approach. However, the Cobiac et al. study compared strategies of different absolute risk thresholds using the average cost-effectiveness ratio of each strategy instead of the ICER.
Our analysis has several strengths. The present study simulated individuals with demographic and clinical profiles based on nationally representative samples of the middle-aged and elderly Chinese population in recent years. Therefore, our model avoided several problems for which cohort Markov models are often criticized. First, the model calculated the absolute risk for everyone using the individual's profile, thereby allowing the treatment decision to be based on the individual's risk. Second, a cohort model would use the average probability (or probabilities) for the population (or subpopulations stratified by risk levels) to model the subsequent life course [13] , while our approach directly used individuals' probabilities for simulation. Third, a cohort Markov model is "memoryless" [50] . This feature makes it difficult for a cohort Markov model to track historical events that may affect subsequent patient costs and outcomes. More, both cohort and microsimulation Markov models are built upon mutually exclusive states, making it challenging to model multiple events in one cycle [13, 51] , whereas our model allowed the occurrence of multiple events in each cycle.
There are several limitations in our study that need to be taken into consideration when interpreting the results. One of the limitations is the ASCVD risk calculation algorithm did not allow direct decomposition of the risk into cardiac death, AMI, and stroke. Hence, an additional step was necessary to retrieve the event-specific risks. A possible drawback of our analysis is that clinical and economic consequences due to non-fatal non-AMI CHD events could not be accounted for. Also, we did not model the effect of persistence, because of a lack of real-world data for long-term statin treatment in China. However, the impact of persistence on ICERs can be partially reflected in the alternative scenarios regarding treatment duration. In addition, the computing burden of our model was tremendous. In fact, the computing burden hindered a more extensive PSA in the current study. Specifically, we were only able to conduct 350 repetitions for the PSA. This was a trade-off for the benefits of using the individual-based simulation approach. Similarly, the number of iterations in each repetition (200,000) was smaller than that in the Pandya et al. study [10] . More, several disutility input data were not Chinese-specific data because of an absence of Chinese-specific data in the literature. Equally important, our model relied on several assumptions (see electronic supplementary material Table S8 ), which is a challenge that is common to simulation studies. Even more, this simulation did not factor in ASCVD risk factor screening because the focus of the current study was on evaluating the risk threshold for treatment when the risks of individuals were given. Finally, we did not model other potential benefits and risks associated with statins, such as reduced advanced/aggressive prostate cancer risk, reduced in-hospital sepsis mortality, statin-induced rhabdomyolysis, and statin-induced diabetes [52] [53] [54] [55] . A stronger evidence base of these benefits and risks is necessary for their inclusion in the assessment.
Conclusions
Among the strategies we evaluated, the 2016 Chinese guideline criteria of initiating statin therapy among people without ASCVD event history is the optimal strategy in China when using the 3-GDP cost-effective standard. When using the 2-GDP standard, the 15% 10-year risk threshold strategy is optimal.
